GSK plc (GSK, GSK.L) announced the European Medicine Agency's Committee for Medicinal Products for Human Use or CHMP has recommended ...

EMA’s human medicines committee recommends approval of GSK’s single-vial, fully liquid presentation of Menveo meningococcal vaccine: London, UK Wednesday, September 25, 2024, ...

Pharmaceutical and biotechnology company GSK said on Tuesday that the European Medicine Agency has recommended meningococcal ...

The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...

with a safety profile consistent with Bexsero and Menveo. GSK’s chief scientific officer, Tony Wood, said that the results show the vaccine protects against “the broadest panel of circulating ...

(Alliance News) - GSK PLC on Tuesday announced a new positive opinion from the EU's European Medicine Agency's Committee for Medicinal Products for Human Use. The London-based pharmaceutical company ...

GSK) has big plans for its future, as it is aiming for GBP38 billion in sales in 2031. Focusing on the present, three of the firm’s top selling products are Menveo and Bexsero which are ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on GlaxoSmithKline (GB:GSK – Research Report), Sonova Holding AG (CH:SOON – Research Report) and Corbus Pharmaceuticals ...

GSK (NYSE:GSK) on Thursday announced its decision to advance its messenger-RNA-based flu vaccine candidate developed with CureVac (NASDAQ:CVAC) into late-stage development following a positive ...

On July 31, GSK released its financial results for the second quarter of 2024, which again beat analysts' expectations by a wide margin. Under Emma Walmsley's leadership, the company is becoming a ...

GSK has demonstrated robust sales growth, with a 13% increase to GBP 7.9 billion and a core operating profit up by 21% to GBP 2.5 billion, as noted by CEO Emma Walmsley in the latest earnings call.

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other cheap pharmaceutical stocks. The pharmaceutical industry is one of the most interesting sectors to ...